Infant Gut Microbiome Composition for SCFA and Immune Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge of establishing and maintaining a healthy microbiome in infants, particularly those with dysbiosis, is addressed by the use of specific bacterial strains and mammalian milk oligosaccharides to increase short-chain fatty acids (SCFA) production and reduce pathogenic bacteria and inflammation.
Innovation Solution
Administering a bacterial composition comprising bacteria capable of colonizing the colon, such as Bifidobacterium and Lactobacillus species, along with mammalian milk oligosaccharides (MMO), either contemporaneously or separately, to promote a healthy microbiome by increasing SCFA levels and reducing pathogenic bacteria and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional teaching is followed to maintain diversity of microorganisms in the microbiome, then stability is improved, but the ability to produce specific beneficial metabolites (SCFA) is reduced
Solution Approach 1:
The patent applies local quality by creating a specialized niche in the infant gut dominated by Bifidobacterium species that have specific functional capabilities (producing SCFA from HMO). Instead of uniform diversity, the invention promotes a localized concentration of specific bacterial strains with optimized metabolic functions for the infant digestive environment.
Solution Approach 2:
The patent changes the ecological parameters of the microbiome by introducing specific bacterial strains (Bifidobacterium longum subsp. infantis) and their substrate (human milk oligosaccharides) to transform the gut environment from a diverse but metabolically less active community to one optimized for SCFA production and immune system maturation.
2Reliability
If bacterial composition is administered to increase SCFA production, then immune system development is improved, but complexity of treatment is increased
Solution Approach 1:
The patent applies universality by selecting Bifidobacterium longum subsp. infantis as a multi-functional probiotic that simultaneously: (1) ferments HMO to produce SCFA, (2) competes with pathogenic bacteria, (3) modulates immune system development, and (4) establishes stable colonization in the infant gut. This single strain addresses multiple health objectives.
Solution Approach 2:
The patent uses human milk oligosaccharides as an intermediary substance that facilitates the beneficial effects of Bifidobacterium. HMO serves as a prebiotic substrate that selectively feeds the probiotic bacteria, enabling their growth and metabolic activity while being indigestible by the infant, thus indirectly supporting immune development through bacterial metabolite production.
3Object-affected harmful factors
If pathogenic bacteria are reduced through targeted treatment, then gut health is improved, but loss of beneficial microbial diversity is increased
Solution Approach 1:
The patent converts the potential harm of antibiotic use (which reduces pathogenic bacteria but also beneficial diversity) into a benefit by using probiotic supplementation. The introduced Bifidobacterium species exploit the ecological niche created by reduced pathogenic load and compete with remaining pathogens while producing beneficial metabolites, thus restoring gut health without relying on broad-spectrum antimicrobials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases SCFA production, particularly acetate and lactate, reduces pathogenic bacteria and inflammation, and stabilizes the gut ecology, thereby enhancing overall health and immune system development in infants.
Implementation Method 1
bacteria capable of and/or activated for colonization of the colon... selected for their growth on mammalian milk oligosaccharides... increase output of acetate and lactate
Data Source
AI summary
The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.